Efficacy evaluation of Hemostatic powder (UI-EWD) for reduction of re-bleeding rate in patients treated with endoscopic therapy for lower gastrointestinal hemorrhage

Aims A novel endoscopic hemostatic powder (UI-EWD/Nexpowder, Nextbiomedical, Incheon, South Korea) was applied for the control of Acute gastrointestinal bleeding (GIB). Although UI-EWD has been demonstrated to be effective in hemostasis in upper-GIB, it is still unclear in lower-GIB. The aim of this study was to evaluate the hemostatic efficacy and safety of UI-EWD applied to Lower-GIB.

Methods We evaluated the effect of UI-EWD in a cohort of Lower-GIB at a single tertiary center in south Korea. One hundred and ninety-eight patients with Lower-GIB who were enrolled from 2017 through 2022 and divided into the conventional treatment group (n = 112) and the UI-EWD treatment group (n = 86). The success rate of immediate hemostasis, re-bleeding rate, and adverse events related to hemostasis were evaluated.

Results Immediate hemostasis was successfully achieved in all patients in both groups. The cumulative re-bleeding rate within 28 days was significantly lower in the UI-EWD treatment group than in the conventional treatment group. (7.0% vs. 17.9%, p = 0.033) There were no UI-EWD related adverse events, such as perforation or embolism was recognized. On the other hand, complications due to mechanical damage of mucosa were observed in the conventional treatment group.

Conclusions Our results showed that the application of UI-EWD in Lower-GIB was safe, effective for immediate hemostasis, and useful for reducing re-bleeding. UI-EWD can be considered as one of the feasible bleeding control modality in Lower-GIB.

Publication History

Article published online:
14 April 2023